Loading
IP
Idera Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Pillar Invest Corp, was filed 19 Jul 2023.
Idera Pharmaceuticals, Inc.: what insiders have been doing
Every trade that managers of Idera Pharmaceuticals, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Nothing new has been filed by managers of Idera Pharmaceuticals, Inc. in twelve months, the latest record being from 11 August 2023.
The full history, which starts in 2016, counts 4 purchases against 6 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
32
Thresholds
n/a
Buy Volume
€173,488
4 ops. · all time
Sell Volume
€54,423
6 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$4.2M
Net income-US$20.1M-480.5% margin
Last declaration on 11 August 2023
Declarations32 total
51 shares@ US$0.51100.0% of flowCommon StockSEC:0001415889-23-012145:0
3,283 shares@ US$0.5331100.0% of flowCommon StockSEC:0001415889-23-012142:0
3,605 shares@ US$1.5812.6% of flowCommon StockSEC:0000899243-23-017445:0
26,965 shares@ US$1.4287.4% of flowCommon StockSEC:0000899243-23-017446:0
Canonical exit: 15 Aug 2023 (T+90)
6,887 shares@ US$1.4018.6% of flowCommon Stock, $0.001 per shareSEC:0001185185-23-000555:0
23,890 shares@ US$1.5068.9% of flowCommon Stock, $0.001 per shareSEC:0001185185-23-000553:0
3,734 shares@ US$1.7512.6% of flowCommon Stock, $0.001 per shareSEC:0001185185-23-000551:0
1,341,764 sharesCommon StockSEC:0001104659-23-005133:0
1,341,764 sharesCommon StockSEC:0001104659-23-005135:0
402,529 sharesCommon StockSEC:0001104659-23-005137:0
33,523 shares@ US$0.446.9% of flowCommon StockSEC:0001415889-23-000919:0
261,718 shares0Common StockSEC:0001415889-23-000766:0
399,218 shares0Common StockSEC:0001415889-23-000764:0
399,218 shares0Common StockSEC:0001415889-23-000765:0
58,516 shares@ US$0.374911.3% of flowCommon StockSEC:0001415889-22-010367:0
5 sharesSeries X Preferred StockSEC:0001578563-22-000031:0
5 sharesSeries X Preferred StockSEC:0001104659-22-104798:0
651,364 sharesCommon Stock, par value $0.001SEC:0001104659-22-104793:0
2,171,214 sharesCommon Stock, par value $0.001SEC:0001104659-22-104797:0
2,171,214 sharesCommon Stock, par value $0.001SEC:0001104659-22-104796:0
1,533,159 shares@ US$0.01100.0% of flowCommon StockSEC:0000899243-22-032038:0
50,086 shares@ US$0.43810.6% of flowCommon StockSEC:0001415889-22-007483:0
41,155 shares@ US$0.53510.1% of flowCommon StockSEC:0001415889-22-003846:0
37,062 shares@ US$0.599.7% of flowCommon StockSEC:0001415889-22-000389:0
10,000 shares@ US$0.615100.0% of flowCommon StockSEC:0001415889-21-006155:0
Canonical exit: 17 Mar 2022 (T+90)
25 of 32 declarations
About Idera Pharmaceuticals, Inc.
IDERA PHARMACEUTICALS, INC. (ticker: IDRA) is a U.S.-listed biopharmaceutical company associated with the American equity market, historically quoted on NASDAQ and referenced in the context of U.S. public-market disclosure and SEC reporting. For international investors, the key point is that the company’s corporate history has undergone a major strategic reset: it was incorporated in Delaware in 1989, operated for many years under the Idera Pharmaceuticals name, and then changed its name to Aceragen, Inc. in 2023. Its operating base was consolidated in Exton, Pennsylvania, in the United States. Those details matter because recent SEC filings and company communications may appear under the newer corporate name rather than the legacy Idera label.([sec.gov](https://www.sec.gov/Archives/edgar/data/861838/000110465923080022/tm2320771-1_pre14a.htm?utm_source=openai))
The business is best characterized as a clinical-stage biotech focused on rare diseases with small, well-defined patient populations and high unmet medical need. Rather than a broad commercial pharmaceutical model, the company’s strategy centers on advancing niche drug candidates through development and, if successful, toward eventual commercialization. Public disclosures highlight lead programs such as ACG-701, a proprietary sodium fusidate formulation being developed for acute pulmonary exacerbations in cystic fibrosis and for melioidosis, as well as ACG-801 for Farber disease. This pipeline indicates a rare-disease orientation with potential regulatory advantages, but also high clinical and financing risk.([nasdaq.com](https://www.nasdaq.com/press-release/idera-pharmaceuticals-acquires-aceragen-2022-09-28?utm_source=openai))
Read moreShow less
From a competitive standpoint, IDERA is a small specialist rather than a large diversified pharma group. Its value proposition depends on clinical differentiation, orphan-disease economics, and the ability to unlock value from a limited number of assets. In this segment, the company competes indirectly with larger biopharma firms, specialty drug developers, and academic-to-commercial translational pipelines, but its real competitive edge must come from execution: clinical data, regulatory milestones, intellectual-property protection, and access to capital. The company has also been shaped by corporate actions over time, including the acquisition of Aceragen in 2022 and the subsequent rebranding in 2023, which underscore a history of strategic repositioning.([nasdaq.com](https://www.nasdaq.com/press-release/idera-pharmaceuticals-acquires-aceragen-2022-09-28?utm_source=openai))
Geographically, the company’s roots are in the United States, with principal operations centered in Pennsylvania. Its investor profile therefore fits the pattern of a U.S. micro-cap biotech: limited current commercial scale, potentially meaningful upside from late-stage clinical success, and elevated downside if trials, funding, or regulatory steps disappoint. Recent notable developments include the Aceragen acquisition, the name change, and continued emphasis on rare pulmonary and rheumatic disease programs. For investors monitoring SEC Form 4 insider transactions, the stock is best viewed as a high-beta event-driven biotech where insider activity, clinical readouts, and capital-market actions can move the equity materially.([nasdaq.com](https://www.nasdaq.com/press-release/idera-pharmaceuticals-acquires-aceragen-2022-09-28?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
